Oragenics, Inc. (OGEN), Wednesday announced that its Board of Directors has approved a 1-for-30 reverse stock split of the company's issued and outstanding shares of common stock, par value $0.001 per share.
As a result, every 30 pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of holders, the company added.
Oragenics expects the reverse split to be effective on June 3, 2025.
In the pre-market hours, OGEN is trading at $0.18, down 3.80 percent on the New York Stock Exchange American.
For comments and feedback: editorial@rttnews.com